Amniotics
0.004 SEK -2.56%2 investors are following this company
Amniotics develops and manufactures stem cell therapies in our own GMP certified facility. Amniotics was born out of the discovery of a novel source of stem cells in full-term amniotic fluid. Based on a decade of research at the internationally recognized Lund University Stem Cell Center and Hospital, the company is pioneering the harvesting and propagation of tissue-specific neonatal quality mesenchymal stem cells (MSC). The company is listed at Nasdaq First North Growth Market in Stockholm.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
AMNI
Daily low / high price
0.004 / 0.004
SEK
Market cap
10.39M SEK
Turnover
50.32K SEK
Volume
13M
Latest videos
Financial calendar
General meeting
2024-05-22
Interim report
2024-08-20
Annual report
2025-02-18
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
LSCS Invest AB | 10.6 % | 10.6 % |
Deflexum AB | 10.3 % | 10.3 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Uttalande från styrelsen i Amniotics med anledning av uppköpserbjudandet från Magle Chemoswed
Amniotics secures short-term capital needs by extending loan agreement and entering into a service agreement
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools